Category: FDA
Federal “Right to Try”: Don’t Disregard Your State Laws Just Yet!
How Federal Preemption (or Lack Thereof) Could Influence the Use of Federal “Right to Try”
As discussed in our Alert of June 4, “Right to Try” Comes to the Federal Stage: What Stakeholders Should Do Now , manufacturers, patients, providers and IRBs are now grappling with two alternative federal pathways through which manufacturers may (but are not required) to provide investigational drugs for treatment...
If the Federal “Compassionate Use” Program is Flawed, Are State “Right to Try” Laws the Solution?
Whether or not you agree with its position, there is no denying that in its recently released report, “Dead on Arrival,” the Goldwater Institute takes a passionate stance on the current status of the federal “Compassionate Use” program and its counterpart, the increasingly vigorous state-led initiative known as the...
